Prachi Kothari

Prachi Kothari

Auto-generated profile, based on publicly available information

Prachi Kothari

Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2018 in The Journal of Pathology
Verified
Journal Article
Open access
PDF file
CSCaitlin M Stewart
Caitlin M Stewart
PKPrachi D Kothari
Prachi D Kothari
FMFlorent Mouliere
Florent Mouliere
RMRichard Mair
Richard Mair
SSSaira Somnay
Saira Somnay
DTDana Wai Yi Tsui
Dana Wai Yi Tsui
Over the past decade, advances in molecular biology and genomics techniques have revolutionized the diagnosis and treatment of cancer. The technological advances in tissue profiling have also been applied to the study of cell‐free nucleic acids, an area of increasing interest for molecular pathology. Cell‐free nucleic acids are released from tumour cells into the surrounding body fluids and can be assayed non‐invasively. The repertoire of genomic alterations in circulating tumour DNA (ctDNA) is reflective of both primary tumours and distant metastatic sites, and ctDNA can be sampled multiple times, thereby overcoming the limitations of the analysis of single biopsies. Furthermore, ctDNA can be sampled regularly to monitor response to treatment, to define the evolution of the tumour genome, and to assess the acquisition of resistance and minimal residual disease. Recently, clinical ctDNA assays have been approved for guidance of therapy, which is an exciting first step in translating cell‐free nucleic acid research tests into clinical use for oncology. In this review, we discuss the advantages of cell‐free nucleic acids as analytes in different body fluids, including blood plasma, urine, and cerebrospinal fluid, and their clinical applications in solid tumours and haematological malignancies. We will also discuss practical considerations for clinical deployment, such as preanalytical factors and regulatory requirements. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

7 July 2020 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
PKPrachi Kothari
Prachi Kothari
FMFrancesco Marass
Francesco Marass
JYJulie L. Yang
Julie L. Yang
CSCaitlin M. Stewart
Caitlin M. Stewart
DSDennis Stephens
Dennis Stephens
DTDana Wai Yi Tsui
Dana Wai Yi Tsui
Purpose: The enucleation rate for retinoblastoma has dropped from over 95% to under 10% in the past 10 years as a result of improvements in therapy. This reduces access to tumor tissue for molecular profiling, especially in unilateral retinoblastoma, and hinders the confirmation of somatic RB1 mutations necessary for genetic counseling. Plasma cell‐free DNA (cfDNA) has provided a platform for noninvasive molecular profiling in cancer, but its applicability in low tumor burden retinoblastoma has not been shown. We analyzed cfDNA collected from 10 patients with available tumor tissue to determine whether sufficient tumorderived cfDNA is shed in plasma from retinoblastoma tumors to enable noninvasive RB1 mutation detection.Methods: Tumor tissue was collected from eye enucleations in 10 patients diagnosed with advanced intra‐ocular unilateral retinoblastoma, three of which went on to develop metastatic disease. Tumor RB1 mutation status was determined using an FDA‐cleared tumor sequencing assay, MSK‐IMPACT. Plasma samples were collected before eye enucleation and analyzed with a customized panel targeting all exons of RB1.Results: Tumor‐guided genotyping detected 10 of the 13 expected somatic RB1 mutations in plasma cfDNA in 8 of 10 patients (average variant allele frequency 3.78%). Without referring to RB1 status in the tumor, de novo mutation calling identified 7 of the 13 expected RB1 mutations (in 6 of 10 patients) with high confidence.Conclusion: Plasma cfDNA can detect somatic RB1 mutations in patients with unilateral retinoblastoma. Since intraocular biopsies are avoided in these patients because of concern about spreading tumor, cfDNA can potentially offer a noninvasive platform to guide clinical decisions about treatment, follow‐up schemes, and risk of metastasis.

16 March 2021 in Ophthalmology Science
Verified
Journal Article
Open access
DADavid H. Abramson
David H. Abramson
DMDiana Mandelker
Diana Mandelker
JFJasmine H. Francis
Jasmine H. Francis
IDIra J. Dunkel
Ira J. Dunkel
ABA. Rose Brannon
A. Rose Brannon
DTDana W.Y. Tsui
Dana W.Y. Tsui
Analysis of circulating tumor DNA (ctDNA) in the plasma of patients with retinoblastoma and simulating lesions. Retrospective cross-sectional study of the association of plasma ctDNA from retinoblastoma and simulating lesions with disease course. Fifty-eight Memorial Sloan Kettering Cancer Center patients with retinoblastoma comprising 68 plasma ctDNA samples and 5 with retinoblastoma-simulating lesions. The ctDNA analyzed with hybridization capture and next-generation sequencing in blood (plasma) of patients who had retinoblastoma or simulating lesions were evaluated for association with clinical course of the disease. Presence or absence of molecular aberrations in the RB1 gene and correlations with clinical features. RB1 cell-free DNA (cfDNA) was detected in 16 of 19 patients with newly diagnosed, untreated intraocular retinoblastoma and in 3 of 3 patients with newly diagnosed, untreated metastatic disease. It was also present in 3 patients with recurrent intraocular disease before therapy, but was not present in patients with recurrent disease who received intra-arterial chemotherapy, nor in 21 patients who had undergone enucleation for unilateral disease. In 1 patient who had delayed treatment (insurance reasons) and showed rapid growth of the intraocular tumor, the variant allele frequency increased in 1 month from 0.34% to 2.48%. No RB1 mutations were detected in the cfDNA from plasma of patients with simulating lesions (3 with Coats disease and 1 with persistent fetal vasculature [PFV]). In 2 patients, we identified 2 independent RB1 mutations in plasma. Mutations in RB1 were found in the cfDNA from blood of patients with newly diagnosed, untreated retinoblastoma and in patients who showed disease recurrence in the eye after prior treatment, but not in unilateral retinoblastoma after enucleation Levels of ctDNA increase in patients with progressive disease who did not receive any treatment. High plasma cfDNA levels were detected in patients with newly diagnosed metastatic disease, and these levels decreased after systemic chemotherapy was administered. Further validation is needed for measuring the somatic alterations in cfDNA from blood in retinoblastoma that could provide a promising method of monitoring patients in the future.

7 September 2021 in JCO Precision Oncology
Verified
Journal Article
Open access
PKPrachi Kothari
Prachi Kothari
TSTalia Sauerhaft
Talia Sauerhaft
NBNancy Bouvier
Nancy Bouvier
MRM. Irene Rodriguez-Sanchez
M. Irene Rodriguez-Sanchez
JSJinru Shia
Jinru Shia
MOMichael V. Ortiz
Michael V. Ortiz